AU776058B2 - NY-ESO-1 nonapeptide derivatives, and uses thereof - Google Patents

NY-ESO-1 nonapeptide derivatives, and uses thereof Download PDF

Info

Publication number
AU776058B2
AU776058B2 AU30791/01A AU3079101A AU776058B2 AU 776058 B2 AU776058 B2 AU 776058B2 AU 30791/01 A AU30791/01 A AU 30791/01A AU 3079101 A AU3079101 A AU 3079101A AU 776058 B2 AU776058 B2 AU 776058B2
Authority
AU
Australia
Prior art keywords
isolated
molecule
seq
cell
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU30791/01A
Other languages
English (en)
Other versions
AU3079101A (en
Inventor
Jean-Charles Cerottini
Vincenzo Cerundolo
Ji-Li Chen
Peter Roderick Dunbar
Pedro Romero
Danila Valmori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Cancer Research
University of Oxford
Original Assignee
CHANCELLORS MASTERS
Ludwig Cancer Research
University of Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/440,621 external-priority patent/US6417165B1/en
Priority claimed from US09/514,036 external-priority patent/US6689742B1/en
Priority claimed from US09/676,005 external-priority patent/US6605711B1/en
Application filed by CHANCELLORS MASTERS, Ludwig Cancer Research, University of Oxford filed Critical CHANCELLORS MASTERS
Publication of AU3079101A publication Critical patent/AU3079101A/en
Application granted granted Critical
Publication of AU776058B2 publication Critical patent/AU776058B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU30791/01A 1999-11-15 2000-11-08 NY-ESO-1 nonapeptide derivatives, and uses thereof Ceased AU776058B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/440,621 US6417165B1 (en) 1988-03-27 1999-11-15 NY-ESO-1-peptide derivatives, and uses thereof
US09/440621 1999-11-15
US09/514036 2000-02-25
US09/514,036 US6689742B1 (en) 2000-02-25 2000-02-25 NY-ESO-1 peptide derivatives, and uses thereof
US09/676,005 US6605711B1 (en) 1999-11-15 2000-09-29 NY-ESO-1 peptide derivatives, and uses thereof
US09/676005 2000-09-29
PCT/US2000/042010 WO2001036453A2 (en) 1999-11-15 2000-11-08 Ny-eso-1 nanopeptide derivatives, and uses thereof

Publications (2)

Publication Number Publication Date
AU3079101A AU3079101A (en) 2001-05-30
AU776058B2 true AU776058B2 (en) 2004-08-26

Family

ID=27412062

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30791/01A Ceased AU776058B2 (en) 1999-11-15 2000-11-08 NY-ESO-1 nonapeptide derivatives, and uses thereof

Country Status (5)

Country Link
EP (1) EP1230261B1 (enExample)
JP (1) JP4615805B2 (enExample)
AU (1) AU776058B2 (enExample)
CA (1) CA2390659C (enExample)
WO (1) WO2001036453A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923337D0 (en) * 1999-10-04 1999-12-08 Isis Innovation Binding agents
WO2001055393A2 (en) 2000-01-28 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
EP2292638A3 (en) 2002-09-27 2011-03-23 Ludwig Institute For Cancer Research MAGE-C2 antigenic peptides and uses thereof
CN1910284B (zh) * 2004-01-20 2011-04-06 爱知县 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用
KR20070056042A (ko) 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
US20160017031A1 (en) * 2006-06-01 2016-01-21 Receptor Logic, LLC T cell receptor mimic rl9a
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
EP3676250A4 (en) * 2017-08-30 2021-05-26 Auckland Uniservices Limited PEPTIDE CONJUGATES, CONJUGATION METHODS AND USES THEREOF
CN112442118B (zh) * 2019-08-30 2023-02-14 深圳普瑞金生物药业股份有限公司 一种tcr及其应用
US20210369828A1 (en) * 2020-05-28 2021-12-02 Case Western Reserve University Plant virus based cancer antigen vaccine
WO2025171250A1 (en) * 2024-02-08 2025-08-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nyeso1 tcr for t-cell therapy and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837273T2 (de) * 1997-10-08 2008-01-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen

Also Published As

Publication number Publication date
CA2390659A1 (en) 2001-05-25
CA2390659C (en) 2010-03-02
EP1230261B1 (en) 2008-06-25
AU3079101A (en) 2001-05-30
JP2003533175A (ja) 2003-11-11
JP4615805B2 (ja) 2011-01-19
WO2001036453A2 (en) 2001-05-25
EP1230261A2 (en) 2002-08-14
WO2001036453A3 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
US6605711B1 (en) NY-ESO-1 peptide derivatives, and uses thereof
EP0804231B1 (en) Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
ES2245783T3 (es) Dominio intracelular de la proteina her-2/neu para la prevencion o el tratamiento de neoplasias malignas.
JP5627180B2 (ja) 無差別的にヒト白血球抗体（ｈｌａ）クラスｉｉ分子に結合する腫瘍関連ペプチド
ES2294844T3 (es) Peptidos antigenicos tumorales derivados de ciclofilina b.
US9907842B2 (en) Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer
JP2002520054A (ja) 前立腺癌の治療及び診断のための組成物及び方法
PT2006294E (pt) Peptídeos associados a tumores de ligação à molécula mhc
CN102295682A (zh) Hla-a*1101限制的wt1肽及含有其的药物组合物
JP2008109928A (ja) Ｈｌａクラスｉｉ分子により提示されるｍａｇｅ−ａ１ペプチド
CN101809148A (zh) 神经元和脑肿瘤的新型免疫疗法
EP1230261B1 (en) Ny-eso-1 nonapeptide derivatives, and uses thereof
CA2295321C (en) Isolated nona- and decapeptides which bind to hla molecules, and the use thereof
US6660276B1 (en) Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US6417165B1 (en) NY-ESO-1-peptide derivatives, and uses thereof
ES2510493T3 (es) Epítopos T CD4+ de la Survivina y sus aplicaciones
US6689742B1 (en) NY-ESO-1 peptide derivatives, and uses thereof
CN111138521B (zh) 源自于afp抗原的短肽
ES2316191T3 (es) Nueva proteina antigenica tumoral sart-3 y peptido antigenico tumoral de la misma.
US10550166B2 (en) Immunogenic peptides of the cyclin B1 tumor antigen
JP2002527050A (ja) Ｈｌａ−ｂ３５分子に結合する単離ペプチド
US20070105779A1 (en) Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
AU3389500A (en) Cloning of cdna of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer
US7041502B2 (en) Isolated peptides which bind to HLA-B18 molecules and uses thereof
CA2182969A1 (en) Methods for identifying individuals suffering from a cellular abnormality

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND INVENTORS TO ADD: PETER RODERICK DUNBAR AND JI-LI CHEN

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND INVENTION TITLE TO READ: NY-ESO-1 NONAPEPTIDE DERIVATIVES, AND USES THEREOF

MK14 Patent ceased section 143(a) (annual fees not paid) or expired